Literature DB >> 19041059

Early recovery of CD4 T cell receptor diversity after "lymphoablative" conditioning and autologous CD34 cell transplantation.

Jan Storek1, Zhao Zhao, Yiping Liu, Richard Nash, Peter McSweeney, David G Maloney.   

Abstract

T cell diversity posttransplantation is thought to be severely restricted, based on T cell receptor beta-chain immunophenotyping or spectratyping. Using beta-chain sequencing, we studied CD4 T cell diversity in 2 adult patients undergoing "lymphoablative" conditioning with cyclophosphamide (Cy), total body irradiation (TBI), and antithymocyte globulin (ATG) and autologous transplantation of hematopoietic cells depleted of T cells by enrichment for CD34 cells. The indication for the transplantation was systemic sclerosis (SSc) or multiple sclerosis (MS). Pretransplantation, the estimated number of distinct beta chains (the minimum number of CD4 T cell clones) in the 2 patients was 600,000 to 700,000, similar to the number in a healthy control. This number was 200,000 to 500,000 at 1 month posttransplantation and 400,000 to 1,600,000 at 12 months posttransplantation. In conclusion, the number of T cells early after lymphoablative conditioning and autologous CD34 cell transplantation may be more diverse than previously appreciated, possibly because many T cell clones survive the conditioning or are reinfused with the graft. Thus, the therapy may not be completely T cell lymphoablative.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19041059      PMCID: PMC2704065          DOI: 10.1016/j.bbmt.2008.09.013

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  40 in total

1.  Characterization of T cell repertoire in patients with graft-versus-leukemia after donor lymphocyte infusion.

Authors:  E J Claret; E P Alyea; E Orsini; C C Pickett; H Collins; Y Wang; D Neuberg; R J Soiffer; J Ritz
Journal:  J Clin Invest       Date:  1997-08-15       Impact factor: 14.808

2.  T-cell repertoire complexity after allogeneic bone marrow transplantation.

Authors:  E Roux; C Helg; B Chapuis; M Jeannet; E Roosnek
Journal:  Hum Immunol       Date:  1996 Jun-Jul       Impact factor: 2.850

3.  Analysis of reconstituting T cell receptor repertoires in bone marrow transplant recipients.

Authors:  J Gorski; M Yassai; C Keever; N Flomenberg
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  1995       Impact factor: 4.291

4.  Infectious morbidity in long-term survivors of allogeneic marrow transplantation is associated with low CD4 T cell counts.

Authors:  J Storek; T Gooley; R P Witherspoon; K M Sullivan; R Storb
Journal:  Am J Hematol       Date:  1997-02       Impact factor: 10.047

5.  Autologous hematopoietic stem cell transplantation for autoimmune diseases.

Authors:  A Gratwohl; J Passweg; C Bocelli-Tyndall; A Fassas; J M van Laar; D Farge; M Andolina; R Arnold; E Carreras; J Finke; I Kötter; T Kozak; I Lisukov; B Löwenberg; A Marmont; J Moore; R Saccardi; J A Snowden; F van den Hoogen; N M Wulffraat; X W Zhao; A Tyndall
Journal:  Bone Marrow Transplant       Date:  2005-05       Impact factor: 5.483

6.  Lymphoid reconstitution after autologous PBSC transplantation with FACS-sorted CD34+ hematopoietic progenitors.

Authors:  C Bomberger; M Singh-Jairam; G Rodey; A Guerriero; A M Yeager; W H Fleming; H K Holland; E K Waller
Journal:  Blood       Date:  1998-04-01       Impact factor: 22.113

7.  Restricted TCR repertoire and long-term persistence of donor-derived antigen-experienced CD4+ T cells in allogeneic bone marrow transplantation recipients.

Authors:  M Vavassori; R Maccario; A Moretta; P Comoli; A Wack; F Locatelli; A Lanzavecchia; E Maserati; P Dellabona; G Casorati; D Montagna
Journal:  J Immunol       Date:  1996-12-15       Impact factor: 5.422

8.  Reconstitution of the T-cell compartment after bone marrow transplantation: restoration of the repertoire by thymic emigrants.

Authors:  F Dumont-Girard; E Roux; R A van Lier; G Hale; C Helg; B Chapuis; M Starobinski; E Roosnek
Journal:  Blood       Date:  1998-12-01       Impact factor: 22.113

9.  Molecular analysis of T-cell receptor repertoire in bone marrow transplant recipients: evidence for oligoclonal T-cell expansion in graft-versus-host disease lesions.

Authors:  X Liu; V Chesnokova; S J Forman; D J Diamond
Journal:  Blood       Date:  1996-04-01       Impact factor: 22.113

10.  Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients.

Authors:  Paolo A Muraro; Daniel C Douek; Amy Packer; Katherine Chung; Francisco J Guenaga; Riccardo Cassiani-Ingoni; Catherine Campbell; Sarfraz Memon; James W Nagle; Frances T Hakim; Ronald E Gress; Henry F McFarland; Richard K Burt; Roland Martin
Journal:  J Exp Med       Date:  2005-02-28       Impact factor: 14.307

View more
  4 in total

Review 1.  Immune mechanisms underlying the beneficial effects of autologous hematopoietic stem cell transplantation in multiple sclerosis.

Authors:  David Gosselin; Serge Rivest
Journal:  Neurotherapeutics       Date:  2011-10       Impact factor: 7.620

Review 2.  Hematopoietic stem cell transplantation for systemic lupus erythematosus.

Authors:  Alberto M Marmont du Haut Champ
Journal:  Clin Dev Immunol       Date:  2012-08-30

3.  Immunological Balance Is Associated with Clinical Outcome after Autologous Hematopoietic Stem Cell Transplantation in Type 1 Diabetes.

Authors:  Kelen C R Malmegrim; Júlia T C de Azevedo; Lucas C M Arruda; Joana R F Abreu; Carlos E B Couri; Gislane L V de Oliveira; Patricia V B Palma; Gabriela T Scortegagna; Ana B P L Stracieri; Daniela A Moraes; Juliana B E Dias; Fabiano Pieroni; Renato Cunha; Luiza Guilherme; Nathália M Santos; Milton C Foss; Dimas T Covas; Richard K Burt; Belinda P Simões; Júlio C Voltarelli; Bart O Roep; Maria C Oliveira
Journal:  Front Immunol       Date:  2017-02-22       Impact factor: 7.561

Review 4.  Regenerating Immunotolerance in Multiple Sclerosis with Autologous Hematopoietic Stem Cell Transplant.

Authors:  Jennifer C Massey; Ian J Sutton; David D F Ma; John J Moore
Journal:  Front Immunol       Date:  2018-03-12       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.